dc.contributor.author |
El-Shewy H.M. |
dc.contributor.author |
Sohn M. |
dc.contributor.author |
Wilson P. |
dc.contributor.author |
Lee M.H. |
dc.contributor.author |
Hammad S.M. |
dc.contributor.author |
Luttrell L.M. |
dc.contributor.author |
Jaffa A.A. |
dc.contributor.editor |
|
dc.date |
May-2012 |
dc.date.accessioned |
2017-10-05T15:30:56Z |
dc.date.available |
2017-10-05T15:30:56Z |
dc.date.issued |
2012 |
dc.identifier |
10.1210/me.2011-1261 |
dc.identifier.isbn |
|
dc.identifier.issn |
08888809 |
dc.identifier.uri |
http://hdl.handle.net/10938/15289 |
dc.description.abstract |
The pro-fibrotic connective tissue growth factor (CTGF) has been linked to the development and progression of diabetic vascular and renal disease.Werecently reported that low-density lipoproteins (LDL) induced expression of CTGF in aortic endothelial cells. However, the molecular mechanisms are not fully defined. Here, we have studied the mechanism by which LDL regulates CTGF expression in renal mesangial cells. In these cells, treatment with pertussis toxin abolished LDL-stimulated activation of ERK1-2 and c-Jun N-terminal kinase (JNK), indicating the involvement of heterotrimeric G proteins in LDL signaling. Treatment with LDL promoted activation and translocation of endogenous sphingosine kinase 1 (SK1) from the cytosol to the plasma membrane concomitant with production of sphingosine-1-phosphate (S1P). Pretreating cells with SK inhibitor, dimethylsphinogsine or downregulation of SK1 and SK2 revealed that LDL-dependent activation of ERK1-2 and JNK is mediated by SK1. Using a green fluorescent protein-tagged S1P1 receptor as a biological sensor for the generation of physiologically relevant S1P levels, we found that LDL induced S1P receptor activation. Pretreating cells with S1P1-S1P3 receptor antagonist VPC23019 significantly inhibited activation of ERK1-2 and JNK by LDL, suggesting that LDL elicits G protein-dependent activation of ERK1-2 and JNK by stimulating SK1-dependent transactivation of S1P receptors. Furthermore, S1P stimulation induced expression of CTGF in a dose-dependent manner that was markedly inhibited by blocking the ERK1-2 and JNK signaling pathways. LDL-induced CTGF expression was pertussis toxin sensitive and inhibited by dimethylsphinogsine down-regulation of SK1 and VPC23019 treatment. Our data suggest that SK1- dependent S1P receptor transactivation is upstream of ERK1-2 and JNK and that all three steps are required for LDL-regulated expression of CTGF in mesangial cells. © 2012 by The Endocrine Society. |
dc.format.extent |
|
dc.format.extent |
Pages: (833-845) |
dc.language |
English |
dc.publisher |
CHEVY CHASE |
dc.relation.ispartof |
Publication Name: Molecular Endocrinology; Publication Year: 2012; Volume: 26; no. 5; Pages: (833-845); |
dc.relation.ispartofseries |
|
dc.relation.uri |
|
dc.source |
Scopus |
dc.subject.other |
|
dc.title |
Low-density lipoprotein induced expression of connective tissue growth factor via transactivation of sphingosine 1-phosphate receptors in mesangial cells |
dc.type |
Article |
dc.contributor.affiliation |
El-Shewy, H.M., Departments of Medicine, Medical University of South Carolina, Charleston, SC 29425, United States |
dc.contributor.affiliation |
Sohn, M., Departments of Medicine, Medical University of South Carolina, Charleston, SC 29425, United States |
dc.contributor.affiliation |
Wilson, P., Departments of Medicine, Medical University of South Carolina, Charleston, SC 29425, United States |
dc.contributor.affiliation |
Lee, M.H., Departments of Medicine, Medical University of South Carolina, Charleston, SC 29425, United States |
dc.contributor.affiliation |
Hammad, S.M., Department of Regenerative Medicine and Cell Biology, Medical University of South Carolina, Charleston, SC 29425, United States |
dc.contributor.affiliation |
Luttrell, L.M., Departments of Biochemistry and Molecular Biology, Medical University of South Carolina, Charleston, SC 29425, United States |
dc.contributor.affiliation |
Jaffa, A.A., Research Service of the Ralph H. Johnson Veterans Affairs Medical Center, Charleston, SC 29401, United States, Department of Biochemistry and Molecular Genetics, Faculty of Medicine, American University of Beirut, Beirut, Lebanon |
dc.contributor.authorAddress |
Jaffa, A. A.; Department of Biochemistry and Molecular Genetics, Faculty of Medicine, American University of Beirut, Riad El-Solh Street, Beirut, Lebanon; email: aj24@aub.edu.lb |
dc.contributor.authorCorporate |
University: American University of Beirut Medical Center; Faculty: Faculty of Medicine; Department: Biochemistry and Molecular Genetics; |
dc.contributor.authorDepartment |
Biochemistry and Molecular Genetics |
dc.contributor.authorDivision |
|
dc.contributor.authorEmail |
aj24@aub.edu.lb |
dc.contributor.faculty |
Faculty of Medicine |
dc.contributor.authorInitials |
El-Shewy, HM |
dc.contributor.authorInitials |
Sohn, M |
dc.contributor.authorInitials |
Wilson, P |
dc.contributor.authorInitials |
Lee, MH |
dc.contributor.authorInitials |
Hammad, SM |
dc.contributor.authorInitials |
Luttrell, LM |
dc.contributor.authorInitials |
Jaffa, AA |
dc.contributor.authorOrcidID |
|
dc.contributor.authorReprintAddress |
Jaffa, AA (reprint author), Amer Univ Beirut, Fac Med, Dept Biochem and Mol Genet, Riad El Solh St, Beirut, Lebanon. |
dc.contributor.authorResearcherID |
|
dc.contributor.authorUniversity |
American University of Beirut Medical Center |
dc.description.cited |
Anelli V, 2010, FASEB J, V24, P2727, DOI 10.1096-fj.09-150540; Bielawski J, 2006, METHODS, V39, P82; Blom IE, 2001, NEPHROL DIAL TRANSPL, V16, P1139, DOI 10.1093-ndt-16.6.1139; Brigstock DR, 2003, J ENDOCRINOL, V178, P169, DOI 10.1677-joe.0.1780169; Chang PY, 2001, CIRCULATION, V104, P588, DOI 10.1161-hc3101.092213; Chiarelli F, 2009, HORM METAB RES, V41, P585, DOI 10.1055-s-0029-1220752; Chowdhury I, 2004, EUR J BIOCHEM, V271, P4436, DOI 10.1111-j.1432-1033.2004.04382.x; Drummond K, 2002, DIABETES, V51, P1580, DOI 10.2337-diabetes.51.5.1580; El-Shewy HM, 2006, J BIOL CHEM, V281, P31399, DOI 10.1074-jbc.M605339200; Estrada R, 2009, HISTOCHEM CELL BIOL, V131, P239, DOI 10.1007-s00418-008-0521-9; Frazier K, 1996, J INVEST DERMATOL, V107, P404, DOI 10.1111-1523-1747.ep12363389; Gaborik Z, 2004, TRENDS ENDOCRIN MET, V15, P286, DOI 10.1016-j.tem.2004.06.009; Gouni-Berthold I, 2004, CELL PHYSIOL BIOCHEM, V14, P167, DOI 10.1159-000078108; Hammad SM, 2010, J LIPID RES, V51, P3074, DOI 10.1194-jlr.D008532; Heusinger-Ribeiro J, 2001, J AM SOC NEPHROL, V12, P1853; Igarashi A, 1998, J CUTAN PATHOL, V25, P143, DOI 10.1111-j.1600-0560.1998.tb01706.x; Jaffa AA, 2008, J CLIN ENDOCR METAB, V93, P1893, DOI 10.1210-jc.2007-2544; Jenkins AJ, 2000, DIABETES, V49, P2160, DOI 10.2337-diabetes.49.12.2160; Jerums G, 2008, DIABETES RES CLIN PR, V82, pS30, DOI 10.1016-j.diabres.2008.09.032; Johnson KR, 2002, J BIOL CHEM, V277, P35257, DOI 10.1074-jbc.M203033200; Kamanna VS, 2002, HISTOL HISTOPATHOL, V17, P497; Katsuma S, 2005, FEBS LETT, V579, P2576, DOI 10.1016-j.febslet.2005.03.073; Katsuma S, 2002, GENES CELLS, V7, P1217, DOI 10.1046-j.1365-2443.2002.00594.x; Katsuma S, 2003, BIOCHEM BIOPH RES CO, V300, P577, DOI 10.1016-S0006-291X(02)02850-4; Kimura T, 2001, J BIOL CHEM, V276, P31780, DOI 10.1074-jbc.M104353200; KLAHR S, 1988, NEW ENGL J MED, V318, P1657; Kyriakis JM, 2001, PHYSIOL REV, V81, P807; Lee MJ, 1998, SCIENCE, V279, P1552, DOI 10.1126-science.279.5356.1552; Li MH, 2008, MOL CANCER RES, V6, P1649, DOI 10.1158-1541-7786.MCR-07-2048; Liu BC, 2003, ACTA PHARMACOL SIN, V24, P67; LOVETT DH, 1983, KIDNEY INT, V23, P342, DOI 10.1038-ki.1983.25; Maceyka M, 2002, BBA-MOL CELL BIOL L, V1585, P193, DOI 10.1016-S1388-1981(02)00341-4; Metzler B, 2000, AM J PATHOL, V156, P1875, DOI 10.1016-S0002-9440(10)65061-4; Moussad EEDA, 2000, MOL GENET METAB, V71, P276, DOI 10.1006-mgme.2000.3059; Muehlich S, 2004, ATHEROSCLEROSIS, V175, P261, DOI 10.1016-j.atherosclerosis.2004.04.011; Murata N, 2000, BIOCHEM J, V352, P809, DOI 10.1042-0264-6021:3520809; Murphy M, 1999, J BIOL CHEM, V274, P5830, DOI 10.1074-jbc.274.9.5830; Oemar BS, 1997, CIRCULATION, V95, P831; Park SK, 2001, BIOCHEM BIOPH RES CO, V284, P966, DOI 10.1006-bbrc.2001.5058; Riser BL, 2000, J AM SOC NEPHROL, V11, P25; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; Sohn M, 2006, AM J PHYSIOL-HEART C, V290, pH1624, DOI 10.1152-ajpheart.01233.2004; Sohn M, 2005, KIDNEY INT, V67, P1286, DOI 10.1111-j.1523-1755.2005.00206.x; Spiegel S, 2003, NAT REV MOL CELL BIO, V4, P397, DOI 10.1038-nrm1103; Spiegel S, 2000, FEBS LETT, V476, P55, DOI 10.1016-S0014-5793(00)01670-7; Taha TA, 2006, BBA-BIOMEMBRANES, V1758, P2027, DOI 10.1016-j.bbamem.2006.10.018; Taha TA, 2004, BBA-MOL CELL BIOL L, V1682, P48, DOI 10.1016-S1388-1981(04)00023-X; Twigg SM, 2002, ENDOCRINOLOGY, V143, P1260, DOI 10.1210-en.143.4.1260; Twigg SM, 2001, ENDOCRINOLOGY, V142, P1760, DOI 10.1210-en.142.5.1760; Velarde V, 2001, J APPL PHYSIOL, V91, P1412; Wahab NA, 2001, BIOCHEM J, V359, P77, DOI 10.1042-0264-6021:3590077; Wang SN, 2003, AM J PHYSIOL-RENAL, V284, pF1006, DOI 10.1152-ajprenal.00382.2002; Wang SN, 2001, KIDNEY INT, V60, P96, DOI 10.1046-j.1523-1755.2001.00776.x; Watterson KR, 2002, J BIOL CHEM, V277, P5767, DOI 10.1074-jbc.M110647200; Wetzker R, 2003, NAT REV MOL CELL BIO, V4, P651, DOI 10.1038-nrm1173; Xin CY, 2006, BRIT J PHARMACOL, V147, P164, DOI 10.1038-sj.bjp.0706452; Xin CY, 2004, J BIOL CHEM, V279, P35255, DOI 10.1074-jbc.M312091200; Yamanaka M, 2004, J BIOL CHEM, V279, P53994, DOI 10.1074-jbc.M410144200; Yatomi Y, 2000, BLOOD, V96, P3431; Zhan B, 2005, ATHEROSCLEROSIS, V178, P199, DOI 10.1016-j.atherosclerosis.2004.08.024; Zhao M, 2002, APMIS, V110, P458, DOI 10.1034-j.1600-0463.2002.100604.x; Zhu Y, 2001, ARTERIOSCL THROM VAS, V21, P1159, DOI 10.1161-hq0701.092473 |
dc.description.citedCount |
7 |
dc.description.citedTotWOSCount |
8 |
dc.description.citedWOSCount |
8 |
dc.format.extentCount |
13 |
dc.identifier.articleNo |
|
dc.identifier.coden |
MOENE |
dc.identifier.pubmedID |
22422617 |
dc.identifier.scopusID |
84860333970 |
dc.identifier.url |
|
dc.publisher.address |
8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA |
dc.relation.ispartofConference |
|
dc.relation.ispartofConferenceCode |
|
dc.relation.ispartofConferenceDate |
|
dc.relation.ispartofConferenceHosting |
|
dc.relation.ispartofConferenceLoc |
|
dc.relation.ispartofConferenceSponsor |
|
dc.relation.ispartofConferenceTitle |
|
dc.relation.ispartofFundingAgency |
|
dc.relation.ispartOfISOAbbr |
Mol. Endocrinol. |
dc.relation.ispartOfIssue |
5 |
dc.relation.ispartOfPart |
|
dc.relation.ispartofPubTitle |
Molecular Endocrinology |
dc.relation.ispartofPubTitleAbbr |
Mol. Endocrinol. |
dc.relation.ispartOfSpecialIssue |
|
dc.relation.ispartOfSuppl |
|
dc.relation.ispartOfVolume |
26 |
dc.source.ID |
WOS:000303864900012 |
dc.type.publication |
Journal |
dc.subject.otherAuthKeyword |
|
dc.subject.otherChemCAS |
mitogen activated protein kinase 1, 137632-08-7 |
dc.subject.otherChemCAS |
mitogen activated protein kinase 3, 137632-07-6 |
dc.subject.otherChemCAS |
n,n dimethylsphingosine, 122314-67-4 |
dc.subject.otherChemCAS |
pertussis toxin, 70323-44-3 |
dc.subject.otherChemCAS |
sphingosine 1 phosphate, 26993-30-6 |
dc.subject.otherChemCAS |
stress activated protein kinase, 155215-87-5 |
dc.subject.otherChemCAS |
Connective Tissue Growth Factor, 139568-91-5 |
dc.subject.otherChemCAS |
Lipoproteins, LDL |
dc.subject.otherChemCAS |
Lysophospholipids |
dc.subject.otherChemCAS |
Phosphotransferases (Alcohol Group Acceptor), 2.7.1.- |
dc.subject.otherChemCAS |
Protein Isoforms |
dc.subject.otherChemCAS |
RNA, Messenger |
dc.subject.otherChemCAS |
RNA, Small Interfering |
dc.subject.otherChemCAS |
Receptors, Lysosphingolipid |
dc.subject.otherChemCAS |
Recombinant Fusion Proteins |
dc.subject.otherChemCAS |
S1PR1 protein, human |
dc.subject.otherChemCAS |
Sphingosine, 123-78-4 |
dc.subject.otherChemCAS |
sphingosine 1-phosphate, 26993-30-6 |
dc.subject.otherChemCAS |
sphingosine kinase, 2.7.1.- |
dc.subject.otherIndex |
2 amino 2 (3 octylphenylcarbamoyl)ethyl phosphate |
dc.subject.otherIndex |
connective tissue growth factor |
dc.subject.otherIndex |
green fluorescent protein |
dc.subject.otherIndex |
guanine nucleotide binding protein |
dc.subject.otherIndex |
low density lipoprotein |
dc.subject.otherIndex |
mitogen activated protein kinase 1 |
dc.subject.otherIndex |
mitogen activated protein kinase 3 |
dc.subject.otherIndex |
n,n dimethylsphingosine |
dc.subject.otherIndex |
pertussis toxin |
dc.subject.otherIndex |
sphingosine 1 phosphate |
dc.subject.otherIndex |
sphingosine 1 phosphate receptor |
dc.subject.otherIndex |
sphingosine kinase 1 |
dc.subject.otherIndex |
sphingosine kinase 2 |
dc.subject.otherIndex |
stress activated protein kinase |
dc.subject.otherIndex |
animal cell |
dc.subject.otherIndex |
article |
dc.subject.otherIndex |
controlled study |
dc.subject.otherIndex |
diabetic angiopathy |
dc.subject.otherIndex |
human |
dc.subject.otherIndex |
human cell |
dc.subject.otherIndex |
kidney injury |
dc.subject.otherIndex |
lipid metabolism |
dc.subject.otherIndex |
lipoprotein metabolism |
dc.subject.otherIndex |
mesangium cell |
dc.subject.otherIndex |
nonhuman |
dc.subject.otherIndex |
priority journal |
dc.subject.otherIndex |
rat |
dc.subject.otherIndex |
Animals |
dc.subject.otherIndex |
Cell Membrane |
dc.subject.otherIndex |
Cells, Cultured |
dc.subject.otherIndex |
Connective Tissue Growth Factor |
dc.subject.otherIndex |
Diabetic Nephropathies |
dc.subject.otherIndex |
Dyslipidemias |
dc.subject.otherIndex |
Gene Silencing |
dc.subject.otherIndex |
Humans |
dc.subject.otherIndex |
Lipoproteins, LDL |
dc.subject.otherIndex |
Lysophospholipids |
dc.subject.otherIndex |
MAP Kinase Signaling System |
dc.subject.otherIndex |
Mesangial Cells |
dc.subject.otherIndex |
Phosphotransferases (Alcohol Group Acceptor) |
dc.subject.otherIndex |
Protein Isoforms |
dc.subject.otherIndex |
Protein Transport |
dc.subject.otherIndex |
Rats |
dc.subject.otherIndex |
Receptors, Lysosphingolipid |
dc.subject.otherIndex |
Recombinant Fusion Proteins |
dc.subject.otherIndex |
RNA, Messenger |
dc.subject.otherIndex |
RNA, Small Interfering |
dc.subject.otherIndex |
Sphingosine |
dc.subject.otherIndex |
Transcriptional Activation |
dc.subject.otherIndex |
Up-Regulation |
dc.subject.otherKeywordPlus |
GLYCOSYLATION END-PRODUCTS |
dc.subject.otherKeywordPlus |
PROTEIN-RELATED PROTEIN-2 |
dc.subject.otherKeywordPlus |
SMAD SIGNALING CASCADE |
dc.subject.otherKeywordPlus |
P38 MAP KINASE |
dc.subject.otherKeywordPlus |
ENDOTHELIAL-CELLS |
dc.subject.otherKeywordPlus |
DIABETIC-NEPHROPATHY |
dc.subject.otherKeywordPlus |
SPHINGOSINE-1-PHOSPHATE RECEPTORS |
dc.subject.otherKeywordPlus |
ATHEROSCLEROTIC LESIONS |
dc.subject.otherKeywordPlus |
LYSOPHOSPHATIDIC ACID |
dc.subject.otherKeywordPlus |
RENAL-DISEASE |
dc.subject.otherWOS |
Endocrinology and Metabolism |